person · Reporting owner

Dere Willard H

Disclosed activity across 7 companies

Tapewire entity: 13975
SEC CIK: 0001311569

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMGEN INCAMGN · Entity 2832	Sr. V.P., Global Dev & CMO	December 13, 2004	December 15, 2004
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404	Director	June 02, 2026	June 04, 2026
Metagenomi Therapeutics, Inc.MGX · Entity 7270	Director	June 09, 2026	June 11, 2026
Ocera Therapeutics, Inc.OCRX · Entity 171193	Director	December 11, 2017	December 11, 2017
Seres Therapeutics, Inc.MCRB · Entity 7191	Director	July 08, 2026	July 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMGEN INC

Report date December 13, 2004 · Filed December 15, 2004

Security / award	Ownership account	Disclosed shares / units	Disclosure context
NQSO (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.95 · Expires 2011-12-13	Direct	13,900	Reported balance After 2004-12-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2004-12-13 · Grant · Acquired 13,900 · Balance 13,900 F1: (WHD 12/04) This option becomes exercisable in four equal installments of 3,475 shares each commencing 12/13/2005.

Filing footnotes · ownership attribution and instrument terms

F1: (WHD 12/04) This option becomes exercisable in four equal installments of 3,475 shares each commencing 12/13/2005.

BIOMARIN PHARMACEUTICAL INC

Report date June 02, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	46,440	Reported balance After 2026-06-02 transaction · row 1 1 source row Row 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 46,440 F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on June 2, 2026. Price not applicable.

Metagenomi Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2036-06-08	Direct	21,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 21,000 · Balance 21,000 F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date.

Ocera Therapeutics, Inc.

Report date December 11, 2017 · Filed December 11, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2017-12-11 transaction · row 1 1 source row Row 1 · 2017-12-11 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.43 · Expires 2026-10-25	Direct	0	Reported balance After 2017-12-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-12-11 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5: (Continued from Footnote 4)All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").

F2: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes.

F3: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes.

F4: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR.

F5: (Continued from Footnote 4)All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore.

F6: This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.

Seres Therapeutics, Inc.

Report date July 08, 2026 · Filed July 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2036-07-07	Direct	6,500	Reported balance After 2026-07-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-08 · Grant · Acquired 6,500 · Balance 6,500 F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Mersana Therapeutics, Inc.

Report date January 06, 2026 · Filed January 06, 2026

Section 16 reporting ended · disclosed 2026-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-01-06 transaction · row 1 1 source row Row 1 · 2026-01-06 · Other · Disposed 1,567 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"), F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08	Direct	Reported balance After 2026-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-01-06 · Disposition to issuer · Disposed 2,460 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $434.50	Direct	Reported balance After 2026-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-01-06 · Disposition to issuer · Disposed 800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.75	Direct	Reported balance After 2026-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-01-06 · Disposition to issuer · Disposed 544 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.75	Direct	Reported balance After 2026-01-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-01-06 · Disposition to issuer · Disposed 1,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.00	Direct	Reported balance After 2026-01-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-01-06 · Disposition to issuer · Disposed 450 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $572.50	Direct	Reported balance After 2026-01-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-01-06 · Disposition to issuer · Disposed 368 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $527.25	Direct	Reported balance After 2026-01-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-01-06 · Disposition to issuer · Disposed 125 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $372.50	Direct	Reported balance After 2026-01-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-01-06 · Disposition to issuer · Disposed 1,002 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $161.00	Direct	Reported balance After 2026-01-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-01-06 · Disposition to issuer · Disposed 513 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.50	Direct	Reported balance After 2026-01-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2026-01-06 · Disposition to issuer · Disposed 1,800 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $216.00	Direct	Reported balance After 2026-01-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2026-01-06 · Disposition to issuer · Disposed 734 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.50	Direct	Reported balance After 2026-01-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2026-01-06 · Disposition to issuer · Disposed 2,200 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

F2: (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

F4: Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

Radius Health, Inc.

Report date August 15, 2022 · Filed August 15, 2022

Section 16 reporting ended · disclosed 2022-08-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2022-08-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-08-15 · Other · Disposed 21,300 · Balance 1,895 F1: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share. Row 2 · 2022-08-15 · Disposition to issuer · Disposed 1,895 · Balance 0 F2: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2032-01-14	Direct	0	Reported balance After 2022-08-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-08-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.

F2: Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share.

F3: Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 25, 2020 Filed Jun 30, 2020 00:09 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	9,200	$0.00 Strike: $22.90	$0.00	Disclosure SEC source: 0001104659-20-078225 · a4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2030-06-25 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2021 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
June 18, 2020 Filed Jun 22, 2020 20:11 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $4.40	$0.00	Disclosure SEC source: 0000899243-20-017353 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The option will vest in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document
May 27, 2020 Filed May 29, 2020 20:23 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,300	$0.00	$0.00	Disclosure SEC source: 0001567619-20-011343 · doc1.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,720 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document
February 26, 2020 Filed Feb 28, 2020 16:15 UTC	Radius Health, Inc. RDUS · Entity 124173	SaleCommon Stock	1,925	$17.95	$34,553.75	Disclosure SEC source: 0001209191-20-013790 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,195 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document
February 20, 2020 Filed Feb 24, 2020 17:49 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock (Right to Buy) · Derivative	10,000	$0.00 Strike: $19.96	$0.00	Disclosure SEC source: 0001209191-20-012139 · doc4.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-20 F2 · derivative.exercise_date: The option vests in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document
February 20, 2020 Filed Feb 24, 2020 17:49 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock	5,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-012139 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,120 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date. Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:38 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	11,264	$0.00 Strike: $5.36	$0.00	Disclosure SEC source: 0001104659-20-000912 · a4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,264 Underlying: Common Stock · 11,264 shares Expires 2030-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020. Read SEC document
June 13, 2019 Filed Jun 14, 2019 20:12 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $2.83	$0.00	Disclosure SEC source: 0000899243-19-017019 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders. Read SEC document
June 07, 2019 Filed Jun 11, 2019 20:14 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	25,000	$0.00 Strike: $4.31	$0.00	Disclosure SEC source: 0001104659-19-034781 · a4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-07 F1 · derivative.exercise_date: The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2020 Annual Meeting of Stockholders of Mersana Therapeutics, Inc. Read SEC document
June 04, 2019 Filed Jun 6, 2019 22:12 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,430	$0.00	$0.00	Disclosure SEC source: 0001567619-19-012975 · doc1.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,420 F1 · price: Restricted stock units granted on June 4, 2019. Price not applicable. Read SEC document
April 16, 2019 Filed Apr 18, 2019 16:41 UTC	Radius Health, Inc. RDUS · Entity 124173	SaleCommon Stock	1,680	$22.22	$37,329.60	Disclosure SEC source: 0001209191-19-025249 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,620 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Read SEC document
February 22, 2019 Filed Feb 26, 2019 18:12 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock (Right to Buy) · Derivative	10,000	$0.00 Strike: $19.18	$0.00	Disclosure SEC source: 0001209191-19-013698 · doc4.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-22 F2 · derivative.exercise_date: The option vests in full on February 22, 2020, subject to continued service with RDUS through such date. Read SEC document
February 22, 2019 Filed Feb 26, 2019 18:12 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantCommon Stock	5,500	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-013698 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 F1 · price: The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 22, 2020, subject to continued service with RDUS through such date. Read SEC document
February 13, 2019 Filed Feb 13, 2019 17:15 UTC	Radius Health, Inc. RDUS · Entity 124173	Exercise / conversionRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0001209191-19-009729 · doc4.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on February 13, 2019. F2 · derivative.expiration_date: The restricted stock units vested in full on February 13, 2019. Read SEC document
February 13, 2019 Filed Feb 13, 2019 17:15 UTC	Radius Health, Inc. RDUS · Entity 124173	Exercise / conversionCommon Stock	4,800	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-009729 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. Read SEC document
January 02, 2019 Filed Jan 4, 2019 21:01 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	13,619	$0.00 Strike: $4.31	$0.00	Disclosure SEC source: 0001104659-19-000777 · a4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,619 Underlying: Common Stock · 13,619 shares Expires 2019-01-02 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2019. Read SEC document
June 26, 2018 Filed Jun 28, 2018 01:07 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	15,000	$0.00 Strike: $9.09	$0.00	Disclosure SEC source: 0000899243-18-018522 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-25 F1 · derivative.exercise_date: The option will vest in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document
June 05, 2018 Filed Jun 8, 2018 00:09 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	4,300	$0.00	$0.00	Disclosure SEC source: 0001140361-18-027782 · doc1.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,990 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document
March 19, 2018 Filed Mar 21, 2018 21:19 UTC	Mersana Therapeutics, Inc. MRSN · Entity 69982	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $17.38	$0.00	Disclosure SEC source: 0001104659-18-019370 · a4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2021-03-19 F1 · derivative.exercise_date: The option becomes exercisable in equal quarterly installments over three years from the date of the grant. Read SEC document
February 13, 2018 Filed Feb 15, 2018 19:36 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantRestricted Stock Units · Derivative	4,800	$0.00	$0.00	Disclosure SEC source: 0001209191-18-010543 · doc4.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Underlying: Common Stock · 4,800 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. F3 · derivative.exercise_date: The restricted stock units shall vest in full on February 13, 2019. F3 · derivative.expiration_date: The restricted stock units shall vest in full on February 13, 2019. Read SEC document
February 13, 2018 Filed Feb 15, 2018 19:36 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	8,800	$0.00 Strike: $37.83	$0.00	Disclosure SEC source: 0001209191-18-010543 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,800 Underlying: Common Stock · 8,800 shares Expires 2028-02-12 F1 · derivative.exercise_date: The option vests in full on February 13, 2019, subject to continued service to the Issuer through such date. Read SEC document
December 11, 2017 Filed Dec 11, 2017 20:19 UTC	Ocera Therapeutics, Inc. OCRX · Entity 171193	Disposition to issuerStock Option (Right to Buy) · Derivative	20,000	Not disclosed Strike: $2.43	Not disclosed	Disclosure SEC source: 0000899243-17-028414 · doc4.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-10-25 F4 · price: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · price: (Continued from Footnote 4)All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · price: This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an "In the Money Option") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR. F5 · derivative.exercise_date: (Continued from Footnote 4)All other options (each, an "Out of the Money Option") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore. F6 · derivative.exercise_date: This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option. Read SEC document
December 11, 2017 Filed Dec 11, 2017 20:19 UTC	Ocera Therapeutics, Inc. OCRX · Entity 171193	Disposition to issuerCommon Stock	12,500	$1.52	$19,000.00	Disclosure SEC source: 0000899243-17-028414 · doc4.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the "Merger Agreement"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the "Issuer"), MAK LLC, a Delaware limited liability company ("Parent"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent ("Purchaser"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser ("Mallinckrodt"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). F2 · price: (Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the "Shares"), of the Issuer outstanding immediately prior to the effective time of the Merger (the "Effective Time") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a "CVR"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the "CVR Agreement"), entered into on December 7, 2017 to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes. F3 · price: At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes. Read SEC document
July 07, 2017 Filed Jul 10, 2017 20:42 UTC	Seres Therapeutics, Inc. MCRB · Entity 7191	GrantStock Option (right to buy) · Derivative	30,000	$0.00 Strike: $11.14	$0.00	Disclosure SEC source: 0000899243-17-018146 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-07-06 F1 · derivative.exercise_date: The option will vest in four equal installments on each anniversary of 07/07/2017 or in full immediately prior to the occurrence of a change in control. Read SEC document
June 20, 2017 Filed Jun 22, 2017 20:42 UTC	Ocera Therapeutics, Inc. OCRX · Entity 171193	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0001274644-17-000061 · wf-form4_149816413114058.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer. Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:18 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantStock Option (right to buy Common Stock) · Derivative	4,910	$0.00 Strike: $89.60	$0.00	Disclosure SEC source: 0001140361-17-024500 · doc1.xml · derivative · entry 2 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018 Read SEC document
June 06, 2017 Filed Jun 8, 2017 22:18 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	2,050	$0.00	$0.00	Disclosure SEC source: 0001140361-17-024500 · doc1.xml · nonDerivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,690 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document
February 17, 2017 Filed Feb 22, 2017 16:23 UTC	Radius Health, Inc. RDUS · Entity 124173	GrantStock Option (Right to Buy) · Derivative	27,500	$0.00 Strike: $45.65	$0.00	Disclosure SEC source: 0001209191-17-013235 · doc4.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date. Read SEC document
October 26, 2016 Filed Oct 28, 2016 13:16 UTC	Ocera Therapeutics, Inc. OCRX · Entity 171193	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $2.42	$0.00	Disclosure SEC source: 0001274644-16-000143 · wf-form4_147766058811862.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2026-10-25 F1 · security: Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Fourth Amended and Restated 2011 Stock Option and Incentive Plan (the "Plan"), qualified under Rule 16b-3(d). F2 · derivative.exercise_date: The option shall vest and become exercisable with respect to 25% of the shares covered by the grant on October 26, 2016, subject to the Reporting Person's continued service to the Issuer through such date, with the balance to vest in equal monthly installments over the next succeeding three year period, subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document
December 13, 2004 Filed Dec 15, 2004 23:25 UTC	AMGEN INC AMGN · Entity 2832	GrantNQSO (Right to Buy) · Derivative	13,900	$0.00 Strike: $63.95	$0.00	Disclosure SEC source: 0001181431-04-059040 · rrd61441.xml · derivative · entry 1 Dere Willard H · CIK 0001311569 · Sr. V.P., Global Dev & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,900 Underlying: Common Stock · 13,900 shares Expires 2011-12-13 F1 · derivative.exercise_date: (WHD 12/04) This option becomes exercisable in four equal installments of 3,475 shares each commencing 12/13/2005. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.